2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…2021 American Transplant Congress
Clinical Impact of Transplant Pharmacists on the Care of Solid Organ Transplant Recipients
1Temple University Hospital, Philadelphia, PA, 2Temple School of Pharmacy, Philadelphia, PA
*Purpose: The United Network for Organ Sharing (UNOS) and Centers for Medicare and Medicaid Services (CMS) requires transplant centers to document the participation of a…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…2021 American Transplant Congress
Impact of the Transplant Clinical Pharmacist in an Outpatient Transplant Clinic
1Emory University Hospital, Atlanta, GA, 2Emory Transplant Center, Atlanta, GA
*Purpose: Pharmacist involvement in the outpatient transplant clinic setting has been correlated with improved patient outcomes in single organ cohort studies. Direct clinical pharmacist involvement…2021 American Transplant Congress
Tacrolimus Dose Requirements in Lung Transplant Recipients on Systemic Azole Antifungals: The Influence of Race and Transplant Indication
*Purpose: CYP3A5 polymorphisms, drug interactions, and alterations in gastric absorption impact tacrolimus metabolism. This is important for those at higher risk of expressing these factors,…2021 American Transplant Congress
Anterior Rectus Sheath versus Standard Gibson Approach to Kidney Transplantation: A Randomized Double-blinded Controlled Trial
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
*Purpose: Purpose: The anterior rectus sheath (ARS) approach to kidney transplantation (KT) involves a small skin incision to incise the ARS and medially retract rectus…2021 American Transplant Congress
Modeling of Alternative Weight-Based Dosing Strategies of LCP-Tacrolimus in De Novo Kidney Transplant Patients
*Purpose: LCP-tacrolimus (LCPT; Envarsus XR®) is a modified-release once-daily formulation approved for prophylaxis of organ rejection in de novo kidney transplant patients in combination with…
- 1
- 2
- 3
- …
- 7
- Next Page »